Physician

Bhavesh Vasant Balar, MD

According to 2025 Medicare claims, Bhavesh Balar, MD (NPI: 1134113376) practices hematology/oncology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Monmouth, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 07728-7904.

Balar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,422 traditional Medicare patients, billed 457,749 HCPCS/CPT codes, and received $7,916,033 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 631 prescription claims across 219 beneficiaries totaling $2,123,209 in drug costs, led by Lonsurf (Trifluridine/Tipiracil Hcl). 2023 DME data shows 13 claims. Open Payments data shows 130 records totaling $3,105. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $4,636,135 to $7,916,033. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	680	318,759	$4,636,135
2016	732	373,228	$5,376,132
2017	837	356,389	$5,296,853
2018	847	412,205	$5,884,947
2019	799	378,315	$4,700,780
2020	776	406,659	$5,505,072
2021	852	466,800	$6,776,950
2022	977	417,467	$7,352,322
2023	1,209	395,002	$7,363,736
2024	1,422	457,749	$7,916,033

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	192	1,002	$2,570,584
2016	210	1,101	$3,013,958
2017	220	981	$2,907,200
2018	237	1,127	$3,500,343
2019	269	1,278	$4,639,805
2020	263	1,235	$4,863,171
2021	245	963	$4,717,163
2022	232	935	$5,439,439
2023	209	701	$3,330,704
2024	219	631	$2,123,209

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	63	$13,001
2018	N/R	31	$7,374
2019	N/R	34	$4,552
2020	N/R	58	$4,636
2021	N/R	34	$2,038
2022	N/R	74	$2,628
2023	N/R	13	$5,022
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	542	1,038	$146
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	672	1,810	$104
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	355	919	$13
36415	Insertion of needle into vein for collection of blood sample	1,036	3,681	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,032	3,693	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lonsurf	Trifluridine/Tipiracil Hcl	11	532	$235,880
Tagrisso	Osimertinib Mesylate	12	360	$196,880
Eliquis	Apixaban	101	6,880	$128,138
Calquence	Acalabrutinib Maleate	15	450	$111,368
Orgovyx	Relugolix	22	660	$56,410

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	128	$3,105	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$9,000	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Bhavesh Vasant Balar, MD?

Tedicare shows public-source Medicare data for Bhavesh Vasant Balar, MD (NPI 1134113376), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bhavesh Vasant Balar, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Bhavesh Vasant Balar, MD?

Bhavesh Vasant Balar, MD is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does Bhavesh Vasant Balar, MD have Open Payments data?

Bhavesh Vasant Balar, MD has 130 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.